Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.

Abstract

Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.

• Authors: Brandon S Imber, Michel Sadelain, Carl DeSelm, Connie Batlevi, Renier J Brentjens, Parastoo B Dahi, Sergio Giralt, Jae H Park, Craig Sauter, Michael Scordo, Gunjan Shah, Miguel-Angel Perales, M Lia Palomba, Joachim Yahalom
• Journal: British journal of haematology (Br J Haematol) Vol. 190 Issue 1 Pg. 45-51 (07 2020) ISSN: 1365-2141 [Electronic] England
• PMID: 32135029 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 British Society for Haematology and John Wiley & Sons Ltd.

Chemical References

• Antigens, CD19
• Receptors, Chimeric Antigen

Topics

• Adult
• Aged
• Antigens, CD19
• Female
• Humans
• Lymphoma, Non-Hodgkin (radiotherapy)
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Receptors, Chimeric Antigen (therapeutic use)
• Salvage Therapy (methods)
• Young Adult